You searched for "information"
Prostate Scotland launches new research project into BPE with support from the Grand Lodge of Scotland
Prostate Scotland has launched a new two-year research project into benign prostatic enlargement (BPE), thanks to long-term funding support from The Grand Lodge of Scotland and Scottish Freemasons. The project aims to build a clearer picture of the experiences of...All you need to know about percutaneous nephrolithotomy: supine versus prone and mini versus traditional
Introduction Since the first percutaneous nephrolithotomy (PCNL), the technique has undergone many innovations, including modifications in positioning, miniaturisation of instruments and combination with retrograde intra-renal surgery (see Table 1 for an outline of the history of the technique). Controversy has...Practical surgical management of chronic testicular pain
Chronic testicular pain (CTP) is defined as constant or intermittent, unilateral or bilateral testicular pain of more than three months’ duration, which significantly interferes with the daily activities of the patient prompting medical advice [1-4]. This condition is commonly seen...So you want to go on a fellowship – part II: the research year
This article is the second in a three-part series which follows directly on from the first part which concentrated on the rationale for going on a fellowship, as well as some of the administrative hurdles you might face in planning...Biomarkers in prostate cancer detection
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...
Bladder Pain Syndrome – An Evolution, 2nd Edition
Bladder pain syndrome remains the focus of much debate and discussion, and this will continue in the future. This book is the second edition of Interstitial Cystitis which was published three decades ago. Given that a lot has happened in...
Performance status may alter outcomes in those treated with abiraterone
The drug therapies available for those with metastatic castrate-resistant prostate cancer have increased over the past few years. Abiraterone, a CYP17 inhibitor, has been proven effective in phase three trials, however those with poor performance status were largely under-represented in...
